The latest interpretation of the efficacy and safety of Icotrokinra (JNJ-2113) in the treatment of moderate to severe plaque psoriasis

On 20254month10, Johnson & Johnson announced the latest data from the ICONIC-LEAD study According to reports, these data mainly focus on the effectiveness and safety of Icotrokinra (JNJ-2113) in the treatment of moderate to severe plaque psoriasis (PsO). This study is the first phase 3 registry to simultaneously evaluate adolescent and adult patients on systemic therapy. The data showed that adolescents treated with Icotrokinra had a significantly higher proportion of skin that was clear or nearly clear at week 16 compared with placebo-treated patients, with no new safety concerns. These data, which will be presented at the annual meeting of the World Congress of Pediatric Dermatology (WCPD) in 2025, further validate the advantages of Icotrokinra as a potential treatment option.

The treatment challenges of plaque psoriasis and the innovative role ofIcotrokinra

Plaque psoriasis (PsO) is an immune-mediated chronic skin disease that causes abnormal proliferation of skin cells and the formation of inflammatory scaly plaques, often accompanied by symptoms such as itching and pain. Traditional treatments usually include topical and oral medications, but their efficacy is limited and their side effects are high. Icotrokinra is a new type of targeted drug designed to selectively block IL-23 receptors, a mechanism that plays a key role in moderate to severe plaque psoriasis and other diseases mediated by IL-23. By precisely targeting the IL-23 receptor, Icotrokinra effectively regulates the immune response, alleviates the symptoms of psoriasis, and provides patients with new treatment options.

ICONIC-LEADStudy design and key data

ICONIC-LEAD is a phase III randomized controlled trial (RCT) designed to evaluate the efficacy and safety of Icotrokinra versus placebo in the treatment of moderate to severe plaque psoriasis. The study included 684patients 12 years old and above, including 456Icotrokinra was treated, and 228 received placebo. The efficacy evaluation criteria are PASI 90 (that is, skin symptoms are significantly improved 90% or above) and IGA score 0/1 (that is, the skin is clear or almost clear). In addition, the IGAscore is a five-point scale, with 0 indicating completely clear skin and 4 indicating the most severe skin symptoms. The results of the study showed that among adolescent patients who received Icotrokinra at 16 weeks, 84.1% achieved IGA With a score of 0/1, 70.5% of patients achieved a PASI 90 response. These data were significantly better than the placebo group, which had IGA 0/1score is 27.3% and PASI 90 is 13.6%.

Long-term efficacy and safety analysis

As treatment continues, the efficacy of Icotrokinra further increases. At week 24, 86.4% of adolescent patients achieved IGA 0/1 and 88.6% achieved PASI 90, showing sustained clinical improvement. In addition, the therapeutic effect of Icotrokinra is also reflected in a higher proportion of patients achieving the goal of completely clear skin (IGA 0), 75%of patients successfully achieved this goal by week 24, and 63.6%of patients achieved PASI 100(i.e. skin completely free of scales). These results show that Icotrokinra can not only significantly improve the skin symptoms of psoriasis patients, but also provide long-term efficacy guarantee.

In terms of safety, Icotrokinra was well tolerated. Approximately 50% of adolescent patients treated with Icotrokinra at week 16 n>At least one adverse event (AE) occurred in 73% of adolescent patients who received placebo. This shows that the incidence of side effects of Icotrokinra is significantly lower than that of the placebo group, and no new safety signals were found in the study. This data further supports the safety of Icotrokinra in adolescent patients.

Summary and future prospects

Icotrokinra (JNJ-2113), as an innovative targeted drug, has demonstrated significant efficacy and good safety in the treatment of moderate to severe plaque psoriasis, especially in adolescents. By selectively blocking the IL-23 receptor, Icotrokinra effectively reduces skin symptoms and improves patients' quality of life. With the release of the ICONIC-LEAD study results, Icotrokinra is expected to become an important option for the treatment of psoriasis in the future, especially for patients who do not respond well to traditional treatments. Future studies will further verify its long-term efficacy and safety and provide more treatment options for psoriasis patients.

References:Eichenfield, L et al. Efficacy and Safety of Icotrokinra, a Novel Targeted Oral Peptide (IL-23R-inhibitor), in Adolescents With Moderate-to- Severe Plaque Psoriasis: Subgroup Analyses From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (ICONIC-LEAD). Presented at the World Congress of Pediatric Dermatology (Abstract #0054). April 2025.